JPRN-UMIN000026577招募中未知
Phase II study of dose escalation and concentration in stereotactic body radiotherapy (SBRT) for metastatic pulmonary or liver tumors from colorectal cancer - Phase II study of SBRT for metastatic pulmonary or liver tumors from colorectal cancer
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1.No apparent interstitial pneumonitis or fibrosis in patients with pulmonary metastasis 2.No liver cirrhosis more than Child-Pugh score 7 in patients with liver metastasis 3.No active inflammation except for using ointment 4.No multiple cancer (except for carcinoma in-situ) 5.No pregnancy or breast feeding 6.No psychiatric disorder 7.No steroid administration 8.No concurrent chemotherapy 9.No fever above 38 10.No cough with opioid drug 11.No other reason that clinician judged as improper
研究者
相似试验
尚未招募
1 期
14F7 in chronic B-cell lymphoproliferative syndromeon-Hodgkin lymphoma, Chronic lymphocytic leukemia, Multiple myelomaRPCEC00000266Center of Molecular Immunology (CIM)142
进行中(未招募)
1 期
Clinical trial using GSK525762 in combination with fulvestrant in subjects with breast cancer.ER-positive Breast CancerMedDRA version: 20.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000115074EUCTR2016-003074-40-FRGlaxoSmithKline Research & Development Limited123
进行中(未招募)
1 期
Study investigation GSK525762 in combination with fulvestrant in treatments of breast cancer.ER-positive Breast CancerMedDRA version: 19.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864EUCTR2016-003074-40-ESGlaxoSmithKline Research & Development Limited300
进行中(未招募)
1 期
Clinical trial using GSK525762 in combination with fulvestrant in subjects with breast cancer.ER-positive Breast CancerMedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864EUCTR2016-003074-40-GBGlaxoSmithKline Research & Development Limited300
进行中(未招募)
1 期
Study to evaluate the effectiveness, safety and tolerability of nivolumab in subjects with advanced liver cancer.MedDRA version: 19.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableSystem Organ Class: 100000004864Hepatocellular carcinomaEUCTR2012-001514-42-DEBristol-Myers Squibb International Corporation570
